ALS
Clinical trials for ALS explained in plain language.
Never miss a new study
Get alerted when new ALS trials appear
Sign up with your email to follow new studies for ALS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New ALS drug combo shows promise in early trial
Disease control CompletedThis study tested a new drug called IFB-088 added to standard riluzole treatment in 51 people with bulbar-onset ALS, a form that affects speech and swallowing first. The goal was to see if the combination is safe and shows signs of slowing the disease over 6 months. Participants …
Matched conditions: ALS
Phase: PHASE2 • Sponsor: InFlectis BioScience • Aim: Disease control
Last updated May 17, 2026 04:39 UTC
-
New ALS drug PrimeC shows promise in Mid-Stage trial
Disease control CompletedThis study tested an experimental drug called PrimeC in 69 people with ALS (Lou Gehrig's disease). Participants took PrimeC or a placebo twice daily for 6 months, and all could continue on the drug for another 12 months. The goal was to check safety and see if PrimeC slows diseas…
Matched conditions: ALS
Phase: PHASE2 • Sponsor: NeuroSense Therapeutics Ltd. • Aim: Disease control
Last updated May 17, 2026 04:15 UTC
-
New oral pill for ALS shows promise in Long-Term safety check
Disease control CompletedThis study looked at the long-term safety of an oral version of edaravone, a medicine for ALS (Lou Gehrig's disease). 185 adults with ALS took the pill for up to 48 weeks. The main goal was to see how many side effects occurred. This is not a cure, but a way to help manage the di…
Matched conditions: ALS
Phase: PHASE3 • Sponsor: Tanabe Pharma America, Inc. • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
ALS patients tolerate oral edaravone in Long-Term safety check
Disease control CompletedThis study looked at the safety of an oral form of edaravone for people with ALS, a progressive nerve disease. Fifteen patients who completed earlier studies took the medicine for 10 days every two weeks. Researchers tracked side effects to see if the drug is safe for long-term u…
Matched conditions: ALS
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated May 12, 2026 13:40 UTC
-
Breathing training shows promise for ALS patients in small study
Symptom relief CompletedThis study looked at whether moderate intensity breathing exercises are safe and doable for people with ALS. Nine adults with ALS did four 3-week cycles of respiratory muscle training at home, with weekly check-ins by video call. The main goals were to see if the training was wel…
Matched conditions: ALS
Phase: NA • Sponsor: Duke University • Aim: Symptom relief
Last updated May 17, 2026 04:16 UTC
-
Spinal clues: new study probes nerve signals to unlock ALS mysteries
Knowledge-focused CompletedThis study compared spinal nerve activity in 101 people—some with ALS and some healthy—to find early signs of the disease. Researchers used gentle electrical, magnetic, or mechanical stimulation to measure how spinal nerves respond. The goal is to develop better ways to diagnose …
Matched conditions: ALS
Phase: NA • Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated May 14, 2026 12:03 UTC